Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Cabozantinib is a multi-kinase inhibitor that has shown significant efficacy in the treatment of a variety of tumors, but its use comes with a number of caveats.What are the precau···【more】
Article source：Captain MedicineRelease date：2025-02-24Recommended：339
Cabozantinib is a multi-targeted tyrosine kinase inhibitor, and special attention should be paid to the details of its use and potential impact in clinical applications.What are th···【more】
Article source：Captain MedicineRelease date：2025-02-24Recommended：289
Cabozantinib is a widely used drug for the treatment of a variety of cancers, and its side effects are of great concern.Does cabozantinib have side effectsExploring the side effect···【more】
Article source：Captain MedicineRelease date：2025-02-21Recommended：256
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has demonstrated significant efficacy in a variety of cancer treatments. However, its accompanying side effects have···【more】
Article source：Captain MedicineRelease date：2025-02-21Recommended：305
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has shown significant efficacy in the treatment of a variety of cancers, but its accompanying side effects are also ···【more】
Article source：Captain MedicineRelease date：2025-02-20Recommended：287
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has attracted much attention in the field of oncology therapy.Does cabozantinib workThe clinical effect of cabozanti···【more】
Article source：Captain MedicineRelease date：2025-02-20Recommended：318
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that plays an important role in cancer treatment, and its therapeutic efficacy has attracted much attention.How effective···【more】
Article source：Captain MedicineRelease date：2025-02-19Recommended：275
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that has demonstrated unique efficacy in cancer treatment, and its therapeutic effect has attracted much attention.Is cab···【more】
Article source：Captain MedicineRelease date：2025-02-19Recommended：283
Cabozantinib is a multi-kinase inhibitor with a wide range of clinical applications. This article will discuss the dosage of cabozantinib and its associated factors, as well as the···【more】
Article source：Captain MedicineRelease date：2025-02-18Recommended：362
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that plays an important role in clinical treatment. This article will detail the use of cabozantinib and its related cons···【more】
Article source：Captain MedicineRelease date：2025-02-18Recommended：387
Cabozantinib is a multi-kinase inhibitor that has demonstrated significant efficacy in the treatment of a variety of tumors. Knowing its recommended dosage is essential to ensure t···【more】
Article source：Captain MedicineRelease date：2025-02-17Recommended：338
Cabozantinib is a multi-targeted tyrosine kinase inhibitor with a wide range of indications in clinical applications.What are the suitable populations for cabozantinib?Cabozantinib···【more】
Article source：Captain MedicineRelease date：2025-02-17Recommended：314
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4472025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6362024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：902026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4142025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4332025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4182025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4742025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3852025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
